HD-OPM Archive
Topics › PCSK9, ezetimibe & newer drugs

Merck's oral PCSK9 pill Lipfendra approved by FDA, cut LDL 56-60% in Phase 3

Gokhan Can · Jul 16, 2026 · ♥ 39 reactions · 43 comments · original Facebook post
PCSK9, ezetimibe & newer drugsLDL, ApoB & lipid panel
AI summary & key facts

Reports FDA approval of Merck's Lipfendra, a once-daily pill delivering PCSK9-inhibitor-type LDL lowering. Phase 3 trials showed LDL reductions of 56% to 60%.

Merck’s newly FDA-approved Lipfendra delivers the powerful cholesterol-lowering effects of a PCSK9 inhibitor in a once-daily pill. The drug reduced LDL by 56% to 60% in Phase 3 trials.

nytimes.comThe F.D.A. Approves a New Pill to Slash Cholesterol LevelsThe new pills can lower cholesterol levels far below what can be achieved with statins, clinical trials have shown.nytimes.com

Research cited

#pcsk9#cholesterol
← newer: Prof Kaeberlein shares his path from CCTA soft plaque to staolder: LDL-C is cumulative exposure: lowering it earlier and longer →